Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/27/2023 | $12.00 → $15.00 | Outperform → Strong Buy | Raymond James |
9/29/2023 | $13.00 | Outperform | Oppenheimer |
6/23/2023 | $13.00 | Outperform | Raymond James |
12/1/2022 | $10.00 | Buy | B. Riley Securities |
11/30/2022 | $6.00 | Outperform | SVB Leerink |
9/16/2022 | $10.00 | Buy | Truist |
7/6/2022 | Outperform | William Blair | |
10/19/2021 | $19.00 | Overweight | Morgan Stanley |
15-12G - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
EFFECT - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
EFFECT - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
SC 13G/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13D - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13D/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
Preliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile Company Prioritizing Cold/Hot Dosing Regimen in Phase 1 Trial; Cohort 2 in this Arm is Currently Enrolling Data to be Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting Fusion to Host Conference Call Tomorrow, Tuesday, June 27th at 4:00 p.m. ET/3:00 p.m. CT HAMILTON, ON and BOSTON, June 26, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of interim data from the do
Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC FPI-1434 preliminary Phase 1 data expected in Q2 2023 FPI-1966 and FPI-2059 Phase 1 trials open and recruiting patients Strong balance sheet with runway into Q1 2025 supports ongoing execution of multiple clinical programs HAMILTON, ON and BOSTON, March 16, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2022 and provided an updat
Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022 Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions HAMILTON, ON and BOSTON, May 11, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2021 and provided an update on clinical and corporate developments. "We continue to advance our Phase 1 study
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that at a special meeting of its shareholders (the "Shareholders"), held virtually earlier today, the Shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act pursuant to which AstraZeneca will acquire all of the issued and outstanding shares of Fusion (the "Arrangement").
AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancerHAMILTON, ON and BOSTON, May 9, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial evaluating FPI-2265 (225Ac-PSMA I&T) in patients with metastatic castration-resistant prostate cancer (mCRPC)."Actinium-based PSMA targeting RCs have demonstrated compelling safety and clinical activity, which is supported by Fusion's encouraging data from the Phase
Raymond James upgraded Fusion Pharmaceuticals from Outperform to Strong Buy and set a new price target of $15.00 from $12.00 previously
Oppenheimer initiated coverage of Fusion Pharmaceuticals with a rating of Outperform and set a new price target of $13.00
Raymond James initiated coverage of Fusion Pharmaceuticals with a rating of Outperform and set a new price target of $13.00
HAMILTON, ON and BOSTON, June 4, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZeneca AB by way of a statutory plan of arrangement under section 192 of the Canada Business Corporations Act, referred to as the Arrangement. The Arrangement marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more
HAMILTON, ON and BOSTON, May 31, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced it has obtained a final order from the Ontario Superior Court of Justice (Commercial List) approving the previously announced statutory plan of arrangement under Section 192 of the Canada Business Corporations Act, pursuant to which a wholly-owned subsidiary of AstraZeneca will acquire all issued and outstanding shares of Fusion (the "Arrangement"). Fusion shareholders will receive US$21.00 per share in cash upfront on completion of the Arrangement plus a deferred
HAMILTON, ON and BOSTON, May 29, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that at a special meeting of its shareholders (the "Shareholders"), held virtually earlier today, the Shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act pursuant to which AstraZeneca will acquire all of the issued and outstanding shares of Fusion (the "Arrangement").
FPI-1434 Phase 1 data on track to be reported in first half of 2023 Phase 1/2 Study of FPI-1966 open and enrolling patients with solid tumors expressing FGFR3 Strong balance sheet with $205.5 million in cash, cash equivalents and investments with runway into Q3 2024 HAMILTON, ON and BOSTON, Nov. 8, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the third quarter ended September 30, 2022 and provided an update on clinical and corporate developments.
HAMILTON, ON and BOSTON, Nov. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer. "We are pleased to welcome Dmitri to Fusion's leadership team at a time when Fusion has three Phase 1 novel targeted alpha therapy (TAT) programs and a multi-product development collaboration with AstraZeneca," said Fusion Chief Executive Officer John Valliant, Ph.D. "Dmitri brings to
- Eric Burak, Ph.D. Appointed as Chief Technology Officer HAMILTON, Ontario and BOSTON, Nov. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer. Dr. Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals. "Chris' expertise and success in radiopharmaceutical research and development is scarce in our